Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Mpagama, Stellah G ^a,b   Houpt, Eric R ^c   Stroup, Suzanne ^c   Kumburu, Happiness ^b   Gratz, Jean ^c   Kibiki, Gibson S ^b   Heysell, Scott K ^c  

^a Kibong'Oto National Tuberculosis Hospital   (Tanzania)

^b KILIMANJARO CLINICAL RESEARCH INSTITUTE   (Tanzania)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Aminoglycosides; embB; Ethionamide; Flouroquinolones; inhA; Minimum inhibitory concentration; Multidrug resistant tuberculosis; Para aminosalicylic acid; pncA; rpoB

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; BACTERIAL DNA; CYCLOSERINE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ETHIONAMIDE; KANAMYCIN; KATG PROTEIN; MOXIFLOXACIN; OFLOXACIN; RIFABUTIN; RNA POLYMERASE BETA SUBUNIT;

ADULT; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG SENSITIVITY; EIS GENE; EMBB GENE; FEMALE; GYRA GENE; HUMAN; KATG GENE; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNCA GENE; QUANTITATIVE ANALYSIS; RPOB GENE; RRS GENE; TANZANIA;

ADULT; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TANZANIA; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84883703774     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-432     Document Type: Article

References (33)

1. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis emergency update 2008, 402. Geneva: WHO/HTM/TB, World Health Organization.
2. World Health Organization Guideline for the programmatic management of drug resistant tuberculosis. Emergency update 2011, Geneva: WHO/HTM/TB, World Health Organization.
3. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010, 182(5):684-692. 10.1164/rccm.201001-0077OC, 20442432.
4. Francis J. Curry National Tuberculosis Center and California Department of Health Drug resistant tuberculosis, a survival guide for clinician 2008, California: California Department of Public Health, Curry National Tuberculosis Center and California Department of Health.
5. Egelund EF, Peloquin CA. Pharmacokinetic variability and tuberculosis treatment outcomes, including acquired drug resistance. Clin Infect Dis 2012, 55(2):2.
6. Heysell SK, Houpt ER. The future of molecular diagnostics for drug-resistant tuberculosis. Expert Rev Mol Diagn 2012, 12(4):11.
7. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010, 51(1):9.
8. Mpagama SG, Heysell SK, Ndusilo ND, Kumburu HH, Lekule IA, Kisonga RM, Gratz J, Boeree MJ, Houpt ER, Kibiki GS. Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania. PLOS One 2013, 8(5):e62034. 10.1371/journal.pone.0062034, 3652861, 23675411.
9. Abuali MM, Katariwala R, LaBombardi VJ. A comparison of the sensititre® MYCOTB panel and the agar proportion method for the susceptibility testing of mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 2011, 31:835-839.
10. Hall L, Jude KP, Clark SL, Dionne K, Merson R, Boyer A, Parrish NM, Wengenack NL. Evaluation of the sensititre® MYCOTB plate for the susceptibility testing of mycobacterium tuberculosis complex against first and second line agents. J Clin Microbiol 2012, 50(11):3732-4. 10.1128/JCM.02048-12, 3486270, 22895034.
11. Rowlinson MC. MICs in TB susceptibility testing: Florida bureau of public health laboratories 2013, San Diego: Eigth National Conference on Laboratory Aspects of Tuberculosis, Association of Public Health Laboratories.
12. World Health Organization Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs 2008, Geneva: WHO/HTM/TB, World Health Organization.
13. Rüsch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006, 44(3):5.
14. Iseman M. Drug-resistant tuberculosis. A Clinician's guide to tuberculosis 2000, 323-350. Philadelphia: Lippincott Williams and Wilkins.
15. Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis 1998, 137:1217-1222.
16. Clinical and Laboratory Standard Institute Performance standards for antimicrobial susceptibility testing; twenty-third information supplement, vol. M100-S23 2013, PA: Wayne, Clinical and Laboratory Standard Institute.
17. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of mycobacterium tuberculosis. Antimicrob Agents Chemother 2011, 55(5):2032-2041. 10.1128/AAC.01550-10, 3088277, 21300839.
18. Cheng AFB, Yew WW, Chan EWC, Chin ML, Hui MMM, Chan RCY. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant mycobacterium tuberculosis clinical isolates. Antimicrobial Agents Chemother 2004, 48(2):596-601.
19. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9(9):153-161.
20. DeBarber AE, Mdluli K, Bosman M, Bekker L, Barry CE. Ethionamide activation and sensitivity in multidrug-resistant mycobacterium tuberculosis. PNAS 2000, 97(17):5.
21. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC. ethA, inhA, and katG loci of Ethionamide-resistant clinical mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003, 47(12):6.
22. Schaaf HS, Victor TC, Venter A, Brittle W, Jordaan AM, Hesseling AC, Marais BJ, van Helden PD, Donald PR. Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis. Int J Tuberc Lung Dis 2009, 13(11):5.
23. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002, 62(15):2169-2183. 10.2165/00003495-200262150-00001, 12381217.
24. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010, 10:9.
25. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006, 10(6):8.
26. Peloquin CA, Hadad DJ, Molino LPD, Palaci M, Boom WH, Dietze R, John JL. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrobial Agents Chemother 2008, 52(3):6.
27. Chigutsa E, Meredith S, Wiesner L, Padayatchi N, Harding J, Moodley P, Mac Kenzie WR, Weiner M, McIlleron H, Kirkpatrick CMJ. Population pharmacokinetics and pharmacodynamics of ofloxacin in south African patients with multidrug-resistant tuberculosis. Antimicrobial Agents Chemother 2012, 56(7):3857-3863.
28. Morlock GP, Crawford JT, Butler WR, Brim SE, Sikes D, Mazurek GH, Woodley CL, Cooksey RC. Phenotypic characterization of pncA mutants of mycobacterium tuberculosis. Antimicrob Agents Chemother 2000, 44(9):5.
29. Jnawali HN, Hwang SC, Park YK, Kim H, Lee YS, Chung GT, Choe KH, Ryoo S. Characterization of mutations in multi- and extensive drug resistance among strains of mycobacterium tuberculosis clinical isolates in republic of Korea. Diag Microbiol Infect Dis 2013, 76(2):187-196.
30. Tupasi TE, Gupta R, Quelapio MI, Orillaza RB, Mira NR, Mangubat NV, Belen V, Arnisto N, Macalintal L, Arabit M, Lagahid JY, Espinal M, Floyd K. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006, 3(9):e352. 10.1371/journal.pmed.0030352, 1564168, 16968123.
31. Resch SC, Salomon JA, Murray M, Weinstein MC. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 2006, 3(7):e241. 10.1371/journal.pmed.0030241, 1483913, 16796403.
32. World Health Organization Second-line drug and anti-TB drug estimation and request tool 2013, http://www.who.int/tb/challenges/mdr/greenlightcommittee/faq6_secondline_drugs/en/ 2013, World Health Organization.
33. Kam KM, Sloutsky A, Yip CW, Bulled N, Seung KJ, Zignol M, Espinal M, Kim SJ. Determination of critical concentration of second-line anti-tuberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis 2010, 14(3):6.